OpenAI isn’t built for health care. So why is its tech already in hospitals, pharma, and cancer care?
OpenAI isn’t built for health care but it’s already inking deals with health care companies.
Related Articles
The antipsychotic drug thiothixene stimulates macrophages to clear pathogenic cells by inducing arginase 1 and continual efferocytosis
Macrophages perform repeated rounds of phagocytosis in response to an FDA-approved dopamine blocker.
Trump throws wrench into NSF’s support for new Texas supercomputer
Spending fight with Congress could force NSF to pull plug on fastest university-based machine
AI drug development’s data problem
The future of drug discovery may be artificial intelligence (AI), but its present is not. AI is in its infancy in the field. To help…
Sexual orientation, gender options cut from U.S. Ph.D. graduate survey
After adding questions to a key survey last year, the U.S. National Science Foundation is reversing course
Make it flow from solid to liquid: Redox-active electrofluids for intrinsically stretchable batteries
A stretchable battery electrode design uses fluids instead of solids to tune its electrochemical and mechanical properties.
Industry Needs More Efficient Viral Vector Production
The main problem is that most vector production technologies were developed for the lab, rather than to support industrial supply,
Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA
Nature Biotechnology – Using G•U wobble base pairs at specific loci increases RNA base-editing precision and efficiency.
Makary says FDA will remove pharma representatives from advisory panels
Representatives from pharma and other industries already play a more limited role in advising the FDA.
Long-Read Sequencing Pinpoints Genetic Basis for Psychiatric Diagnosis in Pediatric Case
Rady study uses PacBio long-read sequencing for RFX3 variant in adolescent patient with autism, showcasing clinical genomics breakthroughs.